Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody ...

Zai Lab Ltd. has entered into a new strategic collaboration and worldwide license agreement with Medilink Therapeutics (Suzhou) Co. Ltd. to use Medilink’s TMALIN antibody-drug conjugate (ADC) platform ...

Researchers from Vera Salus Ricerca Srl and affiliated organizations have reported the discovery and preclinical characterization of novel sigma-1 receptor (S1R) antagonists as potential new analgesic ...

Brainaurora Medical Technology Ltd. debuted on the Hong Kong stock exchange Jan. 8 with a HK$583.18 million (US$74.93 million) IPO, offering about 181.11 million shares at HK$3.22 per share.

Dyne Therapeutics Inc. is eyeing accelerated approval for its myotonic dystrophy type 1 treatment after reviewing new results from a phase I/II study. DYNE-101, an oligonucleotide antisense and DMPK ...

Mural Oncology plc has nominated two new development candidates, one for its interleukin-18 (IL-18) program and one for its IL-12 program.

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a ...

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

Data from two out of three positive studies faced the U.S. FDA’s Anesthetic and Analgesic Drug Products Advisory Committee as members examined the package submitted by Seikagaku Corp., of Tokyo, for ...

Biopharma stocks saw a year of ups and downs in 2024, with the BioWorld Stock Index rising as much as 21% before dipping below 2% and ultimately closing the year up 5.16%. This performance follows a ...